P.A.W. Capital Corp lessened its stake in Johnson & Johnson (NYSE:JNJ) by 10.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,500 shares of the company’s stock after selling 500 shares during the period. P.A.W. Capital Corp’s holdings in Johnson & Johnson were worth $633,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the stock. Altshuler Shaham Ltd bought a new position in Johnson & Johnson in the 1st quarter valued at $35,000. Lake Point Wealth Management lifted its stake in shares of Johnson & Johnson by 144.4% during the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after acquiring an additional 169 shares during the period. Lion Street Advisors LLC bought a new position in Johnson & Johnson in the first quarter valued at about $45,000. Joseph P. Lucia & Associates LLC boosted its holdings in Johnson & Johnson by 50.8% in the first quarter. Joseph P. Lucia & Associates LLC now owns 374 shares of the company’s stock valued at $49,000 after acquiring an additional 126 shares during the last quarter. Finally, Permanens Capital L.P. increased its position in Johnson & Johnson by 100.0% in the first quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock worth $52,000 after purchasing an additional 200 shares during the period. Hedge funds and other institutional investors own 68.44% of the company’s stock.
In related news, EVP Ashley Mcevoy sold 29,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the sale, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.27% of the company’s stock.
Several brokerages have recently issued reports on JNJ. UBS Group lowered shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and reduced their target price for the company from $163.00 to $160.00 in a research note on Tuesday, April 28th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $160.00 to $170.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. ValuEngine cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Wednesday, July 15th. Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their price target for the company from $161.00 to $164.00 in a research note on Monday, July 20th. Finally, Raymond James lifted their price objective on Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $163.38.
NYSE JNJ opened at $145.76 on Friday. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.25 and a quick ratio of 1.05. The firm has a market cap of $386.60 billion, a P/E ratio of 21.31, a P/E/G ratio of 3.25 and a beta of 0.69. The stock’s 50-day moving average is $144.04 and its 200-day moving average is $144.14.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.17. The business had revenue of $18.34 billion during the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. Johnson & Johnson’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same period in the prior year, the business earned $2.58 EPS. Equities analysts anticipate that Johnson & Johnson will post 7.85 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a dividend of $1.01 per share. This represents a $4.04 annualized dividend and a dividend yield of 2.77%. The ex-dividend date of this dividend is Monday, August 24th. Johnson & Johnson’s dividend payout ratio is 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Do stock splits help investors?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.